|Series A, 10/2010 |
|Partial Close, 11/2011 ||$6.61M|
|Series B, 2/2012 |
|Series B, 9/2013 |
BlueTree Capital Group
ALung Technologies, Inc. develops intra and extracorporeal gas exchange devices for the treatment of acute and chronic respiratory disorders. Its products include Hemolung, an extracorporeal gas exchange device that circulates blood through a small catheter; and Hattler Catheter, which is placed within the central venous blood stream in the primary vein that returns blood to the heart and is inserted directly through the skin into the vein. The company serves emphysema, chronic bronchitis, asthma with status asthmaticus, acute respiratory failure, acute respiratory distress syndrome, congestive heart failure with pulmonary edema, neonatal respiratory, and distress syndrome patients, as well as military patients. ALung Technologies, Inc. was founded in 1997 and is based in Pittsburgh, Pennsylvania.